key: cord-0776633-d5egqwws
authors: Pan, Yuehai; Gao, Fei; Zhao, Shuai; Han, Jinming; Chen, Fan
title: Role of the SphK‐S1P‐S1PRs pathway in invasion of the nervous system by SARS‐CoV‐2 infection
date: 2021-02-22
journal: Clin Exp Pharmacol Physiol
DOI: 10.1111/1440-1681.13483
sha: 67beea37a1a5f8ad6c88b2e43135357ed0716547
doc_id: 776633
cord_uid: d5egqwws

Global spread of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is still ongoing. Before an effective vaccine is available, the development of potential treatments for resultant coronavirus disease 2019 (COVID‐19) is crucial. One of the disease hallmarks is hyper‐inflammatory responses, which usually leads to a severe lung disease. Patients with COVID‐19 also frequently suffer from neurological symptoms such as acute diffuse encephalomyelitis, brain injury and psychiatric complications. The metabolic pathway of sphingosine‐1‐phosphate (S1P) is a dynamic regulator of various cell types and disease processes, including the nervous system. It has been demonstrated that S1P and its metabolic enzymes, regulating neuroinflammation and neurogenesis, exhibit important functions during viral infection. S1P receptor 1 (S1PR1) analogues including AAL‐R and RP‐002 inhibit pathophysiological responses at the early stage of H1N1 virus infection and then play a protective role. Fingolimod (FTY720) is an S1P receptor modulator and is being tested for treating COVID‐19. Our review provides an overview of SARS‐CoV‐2 infection and critical role of the SphK‐S1P‐SIPR pathway in invasion of SARS‐CoV‐2 infection, particularly in the central nervous system (CNS). This may help design therapeutic strategies based on the S1P‐mediated signal transduction, and the adjuvant therapeutic effects of S1P analogues to limit or prevent the interaction between the host and SARS‐CoV‐2, block the spread of the SARS‐CoV‐2, and consequently treat related complications in the CNS.

oedema. 2 SARS-CoV-2 infection also can damage other organs, such as the liver, kidneys, heart, and intestines, even causing multiple organ dysfunction syndrome (MODS). 3 Thrombotic complications are evident in some severe COVID-19 patients. 4, 5 Moreover, patients reported ischaemic stroke, acute disseminated encephalomyelitis, and brain damage. 6 There are also some patients who reported neurological and neuropsychiatric dysfunctions. 7 Although there are many reports of neurological symptoms in COVID-19 patients, such as headache, nausea and vomiting, 8 stroke, 2 isolated Guillain-Barré syndrome, 9 and demyelination. 10 However, it is not clear whether the neurological symptoms are transported via synapses to the nervous system or are the result of passing through the blood-brain barrier (BBB) endothelial cells and inflammatory cells reaching the nervous system. In response to SARS-CoV-2 infection, immune cells will be recruited from the circulation to the infected tissues, and these cells will release cytokines in large quantities, which will cause a "cytokine release storm". 2 It is also accompanied by an increased production of a variety of inflammatory mediators including lipid factors, chemokines, cytokines, and extracellular matrix proteins. Overcontrolled immune responses can worsen the condition of COVID-19 patients. 3 Sphingolipids, biologically active signalling molecules, play an important role in both physiological and pathological conditions (viral infections). 11, 12 Sphingosine 1-phosphate (S1P) contributes to determining cell fate through the interaction between ceramide and sphingosine. 13 S1P is a kind of lipid mediator produced by the metabolism of sphingomyelin where is extracellular located. Main functions of SIP include regulating cell-cell and cell-matrix adhesion and affecting cellular migration and differentiation. 14,15 S1P also plays a variety of roles in various disease processes, including inflammation and cancer. 16 S1P has five different cell surface G protein (Gi/o, G12/13, and Gq)coupled receptors, termed S1PR1-5 have been described, which are related to cannabinoid and lysophosphatidic acid receptors. 17 Most cells of vertebrates express S1P receptor subtypes, different types of cells express different subtypes. 14,18 S1P can act as an intracellular mediator or as a receptor-ligand. S1P receptors (S1PRs) bind to S1P with high affinity to induce cellular responses. S1P can be transported across the membrane and released from the intracellular environment to the extracellular environment. 2 S1PRs exhibit unique G protein coupling characteristics with S1PR1 being only coupled to the Gi/o family. S1PR2 can be coupled to the families of Gi/o, G12/13 and Gq, causing the activation of small GTPases such as Rac, Rho, and Ras. 19 Among these five receptors of S1P, S1PR1-3 are mainly expressed in the immune system, central nervous system (CNS) and vascular endothelium. S1PR4 is mainly expressed in lymphatic tissues, while S1PR5 is mainly expressed in the CNS and natural killer cells. 19, 20 Emerging studies have suggested that the activation of S1PR1 plays an important role in the process of newborn neuroblasts moving from the neurogenic niches to the olfactory bulb. 2, 21 S1PRs are highly expressed in the olfactory epithelium. 22 , 23 Netland and colleagues 24 have proved that SARS-CoV has the ability to reach the brain through the olfactory bulb and then causes transneuronal spread to the brain.

Sphingosine-1-phosphate binds to the S1PRs on the outer membrane of the cell, activating the Ras/Raf/ERK signal pathway in order to stimulate DNA synthesis, promote cell growth and cell survival. 25 The Ras/Raf/ERK extracellular signal promotes the production of S1P through sphingosine kinase (SphK), which actually forms a positive feedback loop and blocks the pro-apoptotic function of ceramide. 26 Rho GTPase can be coupled to S1PRs to activate the Hippo signalling pathway and also activate the Hippo signalling related transcriptional effectors. 27 S1P has been proved to regulate the release of free calcium ion in the endoplasmic reticulum 28 (Figure 1 ). Studies have shown that lacking S1P leads to increased vascular leakage, and S1P signalling is essential for angiogenesis and development. 29 S1P has also been reported to perform their functions through other G protein-coupled receptor-independent pathways, such as Histone Deacetylase, 30 TRAF2 31 and Prohibitin 2. 32 SphK and S1P lyase contribute to lymphocyte transport through S1P gradient, playing a role in host inflammatory responses. 33, 34 Sphingosine analogue FTY720 used for the treatment of multiple sclerosis has been extensively studied. 35 Olfactory epithelial cells have relatively high expression and activity of S1P lyase. 22 S1PR1 analogues AAL-R 36 and RP-002 36 inhibit pathophysiological responses in the early stage of H1N1 virus infection. Compared with the antiviral drug oseltamivir, RP-002 is more effective in reducing lung injury, while a combination therapy being more effective than single treatment. 36 The combination of S1PR1 agonist CYM-5442 and antiviral drug oseltamivir can provide a maximum protection against acute lung injury. 37 The use of S1PR agonists has been proved to be effective in reducing acute lung injury caused by viral infection. We propose that S1PR agonists may serve as a new therapeutic approach for treating COVID-19.

The literature review was done through the systematic search for current findings mainly from Google Scholar and the National Centre for Biotechnology Information -PubMed database. The following defined words were used as a search strategy to obtain relevant in- 

Approximately 85% sequences are similar between SARS-CoV-2 and SARS-CoV. 38 The SARS-CoV-2 sequences are almost the same among different infected persons with the sequence homology exceeding 99.9%. 39 This newly emerged virus has 380 amino acids substitution differences in the receptor binding domain with the virus spike (S) protein of human ACE2 being expressed on the surface. 40 Similar to SARS-CoV, SARS-CoV-2 also finds ACE2 in order to invade cells, suggesting that SARS-CoV-2 may target and infect similar cell types as SARS-CoV did. 41 The ACE2 gene is widely expressed in our body including heart, brain, kidneys, eyes, upper respiratory tract, lungs, gut, vasculature, and liver 42 ( Figure 2 ). It has been gradually established that SARS-CoV-2 uses human ACE2 proteins as its receptors in order to enter into the ACE2-expressing cells and SARS-CoV-2 does not use other coronavirus targeting receptors such as dipeptidyl peptidase 4 and aminopeptidase N. 43 Growing evidence confirms that ACE2 is closely associated with lung injury in patients with COVID-19 44 and could also mediate SARS-CoV-2 S-mediated entry into cells. [45] [46] [47] The change of several key amino acid residues leads to the enhancement of hydrophobic interaction and the formation of a salt bridge, making the affinity between SARS-CoV-2 and ACE2 much stronger than that of SARS-CoV. 42, 48 This can be one of the reasons that current global influence of SARS-CoV-2 is far greater than that of SARS-CoV. Emerging data have suggested that sphingosine can competitively bind to the cell receptor ACE2 with SARS-CoV-2 and prevent biological interactions between the viral S protein receptor binding domain and ACE2. 49 This indicates that S1P

can interfere with the interaction between the virus and its receptor to prevent viral infection.

The SARS-CoV-2 S protein has been widely recognized as an important determinant of host tropism, representing a key target for vaccine development. 42, 45 Both SARS-CoV 50 and SARS-CoV-2 45 S protein can downregulate the expression of ACE2 and induce the shedding of the ACE2 extracellular domain. 51 Subsequently, the function of the renin-angiotensin system can be affected, leading to excessive inflammation and vascular permeability. 45, 52 In a study of 12 patients with COVID-19, the level of circulating Ang II levels (linear to viral load) was increased significantly in the COVID-19 group than the healthy control group. 53 This finding indicates a direct relationship between the down-regulated expression of ACE2 and systemic renin-angiotensin system imbalance caused by the SARS-CoV-2 infection. Sphingosine specifically interacts with ACE2. Strikingly, the ability of binding recombinant ACE2 to the SARS-CoV-2 S protein is inhibited significantly after incubating with a low concentration of sphingosine. 49 Amphiphilic sphingosine molecules can bind to the polar and hydrophobic amino acids in the ACE2 pocket, then interacting with the receptor binding domain of the SARS-CoV-2 S protein. [54] [55] [56] Sphingosine may also interact with other domains of ACE2. 49 The interaction of sphingosine and ACE2 may cause the conformational change of the ACE2 inner S-binding domain, thereby preventing binding of virus S protein.

During the early stage of infection rapid replication of the SARS-CoV-2 may cause epithelial and endothelial cellular apoptosis, F I G U R E 1 Schematic diagram describing the signalling pathways transduced by S1PRs. S1P activates the S1PRs, S1PR1-5, which transmits various intracellular signals according to the coupled Gα subunit of the heterotrimeric G protein. S1PR1 is coupled with Gi/o, while S1PR2 and S1PR3 are coupled with Gi/o, Gq and G12/13; S1PR4 and S1PR5 are coupled with Gi/o and G12/13. The signalling through Gi/o is related to the activation of Ras/ERK to promote proliferation and survival, improve survival rate through PI3K/Akt; through PI3K/ Rac promote migration, enhance vascular barrier integrity and vasodilation; increase intracellular Ca 2+ through PKC or PLC. Signalling through Gq mainly activates the PLC pathways. Signalling through G12/13 can promote the activation of Rho/Rho kinase, thereby inhibiting migration, reducing the integrity of the vascular barrier and inducing vasoconstriction. ERK, extracellular signal-regulated kinase; PI3K, phosphatidylinositol 3-kinase; AKT, protein kinase B; PKC, protein kinase C; PLC, phospholipase C vascular leakage, 57 pyroptosis of macrophages and lymphocytes, subsequently triggering the release of pro-inflammatory cytokines and chemokines. 52 Guan et al 58 67 The activation of SphK1 is also related to TNF receptor-associated factor 2, and locally produces S1P, which mediates the activation of TNFα-stimulated nuclear factor kappa B (NF-kB) to promote cell survival and the release of pro-inflammatory mediators. 31 SphK1 activation can also lead to an increase in the production of IL-6 induced by lipopolysaccharide and aggravate the inflammatory response. 68 Although SphK2 also has the same ability to phosphorylate sphingosine to S1P as SphK1, 69 SphK2 is considered to be a negative regulator of inflammation. 70 SphK2 has also been confirmed to exert anti-inflammatory function in human macrophages, and human macrophages are the main regulator of inflammation, its overexpression inhibits the transcriptional activity of NF-κB and the release of cytokines. 71 The early degradation of SphK2 can cause the activation of macrophages, and the late upregulation of SphK2 may be involved in the termination of the production of inflammatory cytokines. 71 In the process of SARS-CoV-2 invading cells, both S-protein and ACE2 are proteolytically modified by host cell proteases. 42, 72 So host cell proteases also play a key role in the process of SARS-CoV-2 invasion. It has been proven that SARS-CoV-2 can use a variety of host proteases, 42 including cathepsin L/B, factor X, trypsin, elastase, transmembrane protease serine 2 (TMPRSS2) and furin to trigger S protein and promote cell entry after receptor binding. 73

In most COVID-19 cases, the virus spreads along the upper respiratory tract, resulting in limited clinical manifestations. There are also a small number of COVID-19 cases of SARS-CoV-2 reaching the lungs and preferentially affecting type II alveolar cells, leading to F I G U R E 2 Schematic diagram of the main expression of ACE2 in the whole body. ACE2 is expressed in the circumventricular organs of the CNS, upper respiratory tract (goblet and ciliated epithelial cells), the vascular system (endothelial cells, migratory angiogenic cells, and vascular smooth muscle cells), alveolar Type II epithelial cells of the lungs, and pulmonary vasculature, the liver (cholangiocytes and hepatocytes), enterocytes of the gut, kidneys (glomerular endothelial cells, podocytes, and proximal tubule epithelial cells), heart (cardiofibroblasts, cardiomyocytes, endothelial cells, pericytes, and epicardial adipose cells), eyes (pigmented epithelial cells, rod, and cone photoreceptor cells and Müller glial cells) serious diseases or possibly entering the brain through some way.

are highly susceptible to the virus, 74 lung and brain infections were observed in all mice after intranasal inoculation, 75, 76 confirming that SARS-CoV infects the brain through olfactory receptor neurons.

Although the expression level of human ACE2 in the brain does not exceed 0.1%-1% of the lungs, 24 the level of virus replication in the lungs of these mice is high, but extensive virus replication has also been detected in the brain, SARS-CoV may use a transneuronal/synaptic pathway that uses axon transport in the brain, 75, 77 which is also true for SARS-CoV-2. Studies showed that SARS-CoV-2 enters the endoplasmic cavity in the early and late stages in non-neuronal cells; therefore, it may be directed to the vesicular axon pathway of neurons. 78, 79 ACE2 is encoded in neurons, oligodendrocytes and astrocytes, and is also found in the substantia nigra, posterior cingulate cortex, middle temporal gyrus, and ventricles. 80 There are regional differences in the degree of infection in the brain, some areas of the brain (such as the cerebellum) are uninfected, while other areas (such as the thalamus, cerebrum, and brainstem) are severely infected. 24, 75 There is about a 60-h delay from nasal infection to the detection of SARS-CoV in the olfactory bulb. 79 Within these 60 h, the virus may replicate and accumulate in different olfactory epithelial cells, because its subsequent transport to other parts of the brain requires a relatively short time. 79 Considering the similarities between SARS-CoV and SARS-CoV-2, the same is true for SARS-CoV-2.

In humans, the cells co-expressing ACE2 and protease (such as TMPRSS2) are not only upper respiratory tract epithelial cells. 81 After querying the previously published large amounts of RNAseq data from the entire olfactory mucosa of macaques, marmosets, and humans, 82, 83 it was found that all olfactory mucosa samples expressed almost all genes related to SARS-CoV-2 entry.

Immunostaining of human olfactory neuroepithelial biopsy tissues confirmed the expression of ACE2 protein, revealing the expression of ACE2 in horizontal basal cells and sustentacular cells, while there is no ACE2 protein expressed in olfactory sensory neurons. 82 The olfactory epithelium is a pseudo-layered epithelium composed of basal cells (ie stem cells), sensory neurons, supporting cells. 84 In human olfactory epithelium, sustentacular cells and olfactory stem cells may be the direct targets of SARS-CoV-2. And sustentacular cells have the highest expression frequency of ACE2 85,86 (2.9%), although the frequency is slightly lower than that observed in respiratory cilia showed that most TMPRSS2 is expressed in sustentacular cells, but the expression level in mature olfactory receptor neurons is very low. 82, 86, 87 Although the expression level of SARS-CoV-2 entryrelated genes in the olfactory epithelium is lower than that in the respiratory epithelium isolated from the nasal mucosa, it was found that the co-expression levels of ACE2 and TMPRSS2 in human olfactory epithelial sustentacular cells were similar to those observed in the rest of the non-nasal respiratory tract. 82, 88 The co-expression of TMPRSS2 and ACE2 with their higher expression levels make sustentacular cells more susceptible to SARS-CoV-2 infection 86 ( Figure 3 ).

In addition to the olfactory axon pathway, SARS-CoV-2 may also be directly transmitted from non-neuroolfactory epithelial cells to the cerebrospinal fluid surrounding the olfactory nerve bundle, located near the cribriform plate. 79 Once SARS-Cov-2 enters the cerebrospinal fluid, it can reach most areas of the brain, including the medulla oblongata. More severe pneumonia can cause systemic hypoxia, which can cause brain damage. Factors that cause damage include peripheral vasodilation, hypercapnia, accumulation of toxic compounds, anaerobic metabolism and hypoxia. These may lead to neuron swelling and brain oedema, and ultimately to nervous system damage. 89 Sphingosine-1-phosphate can promote the olfactory ensheathing cells' proliferation in vivo and in vitro through the S1PR1/RhoA/ Yes-associated protein pathway, thereby promoting the projection of the olfactory nerve layer and axons, and the growth of olfactory neurons to the olfactory bulb. 23 S1P plays a key role in stem cells proliferation and olfactory sensory neuron function. S1PRs show different tissue expressions, and S1PRs are highly expressed in the olfactory epithelium both in vitro and in vivo. 23 S1P lyase is an essential enzyme for S1P degradation, it generates S1P chemical gradient and promotes lymphocyte trafficking. 90 S1P lyase is also highly expressed in the CNS, including the cerebral cortex, cerebellum, arachnoid lining cells, choroid plexus, specific neurons of the olfactory bulb, the spinal cord, trigeminal nerve ganglion, midbrain, and hindbrain. 90 Olfactory neurons are one of the tissues that express S1P lyase most strongly around the olfactory bulb. 90 Sphingosine-1-phosphate proved to be a powerful neurogenesis stimulant. 91 S1PRs are expressed in different neural progenitor stem cells and different neural cell types. 92 The ATP-binding cassette transporter has been confirmed as an S1P transporter for various types of normal cells and tumor cells. 16 One of the Major Facilitator Superfamily (MFS) named spinster homologue 2, which hasn't a typical ATP-binding motif, was identified as promoting S1P output in the heart and brain. 93 MFS domain-containing 2b (MFSd2b) is also an S1P transporter, which is essential for exporting bioactive lipids from endothelial cells in the brain. 94 The study found that by deleting the gene encoding S1P lyase type 1 (SGPL1) in mice, S1P could accumulate in the brain and then determined the activation of microglia and IL-6 secretion; this process was related to defective autophagy and was caused by S1P/S1PR2 axis mediated. 95 

Generally, the severity of symptoms depends on the patient's immune system status and age, the mortality rate is higher in individuals with weakened immune function and those older than critically ill patients suffer from one or more coexisting underlying diseases, such as diabetes, and cardiovascular diseases, hypertension. 102,103 SARS-CoV-2 also has a high affinity for the cardiovascular system, which can lead to acute cardiovascular-related diseases such as congestive heart failure, cerebral medullary cardiopulmonary dysfunction, and other chronic heart diseases. [104] [105] [106] The main cause of death in patients with COVID-19 is respiratory failure, occurring mostly in older people, people with weakened immunity, and patients with other potential health problems. 43, 107 F I G U R E 3 Left: Schematic diagram of the distribution of olfactory bulb, olfactory epithelium, and respiratory epithelium in the nasal cavity: The sagittal view of the human nasal cavity, the arrow points out the position of the olfactory bulb, olfactory epithelium, and respiratory epithelium. Right: Anatomical diagram of the olfactory epithelium and the main known cell types, schematic diagram of SARS-Cov-2 invasion of the olfactory epithelium. The olfactory epithelium is mainly composed of olfactory cilia, microvilli, olfactory sensory neurons, sustentacular cells, immature neurons, globular basal cells, horizontal basal cells, Bowman's glands. The expression of ACE2 receptor, S1PR, and S1P transporter is shown in supporting cells and neuronal cells. Some of these cells are the direct targets of SARS-CoV-2. The reduced nutritional support caused by damaged sustentacular cells infected by SARS-CoV-2 may lead to impaired basal cell renewal

Severe acute respiratory syndrome coronavirus 2 infection primarily affects the respiratory system; therefore, the clinical symptoms of COVID-19 are predominantly respiratory. But, it is not uncommon for the nervous system to be affected. If it is not detected and treated early, it can lead to serious complications. Under normal circumstances, neurological complications appear in severely ill patients, and sometimes they may even appear earlier than respira- in China. 132 The vaccine was modified to express the SARS-CoV-2's S protein using human adenovirus type 5 as vector. 132 This vector has previously been used in the Ebola vaccine Ad5-EBOV and has shown good safety in clinical trials. 133 It was found in clinical trials that the vaccine can induce neutralizing antibodies and specific T cell responses. 134 The WHO maintains a running list of candidate vaccines in development, and as of December 2nd 2020, there were 51 candidate vaccines in clinical evaluation (Table S1 ).

Sphingolipid signalling plays an indispensable role in virus replication, immune response activation, and maintenance of vascular system integrity. 67 Edwards et al. 49 Fingolimod is one of the most unique sphingolipid-based drugs and is currently the main drug candidate for the treatment of COVID-19. Activated FTY720 is a paradox that acts as both an antagonist and an agonist. 67 FTY720 is a non-selective agonist of four out of five G-protein-coupled S1PRs, namely S1PR1, 3, 4, and 5. 67 Different from naturally occurring S1P, activated FTY720 acts as a selective antagonist of S1PR1 by specifically inducing the internalization and down-regulation of S1PR1. 135 FTY720 is a kind of sphingosine analogue and also requires SphK for activation and phosphorylation. 136 FTY720 also can act as a substrate and transforms into active state, compared with SphK1, FTY720 is activated by the action of SphK (SphK1,2) isoenzymes and has a higher affinity for SphK2. 137 The potential positive effect of FTY720-P's antagonism against S1PR1 in the treatment of SARS-Cov-2 infection is to inhibit excessive inflammation or "the cytokine storm". 67 FTY720-P can reduce excessive inflammation causes blood vessel damage. Lymphocytes usually circulate between blood with higher S1P levels and lymphatic tissues with lower S1P levels. Through gradient adjustment, S1P binds to S1PR1, S1PR3, S1PR4, and S1PR5 on lymphocytes. 67 The combination of FTY720-P with S1PR1 on lymphocytes firstly cause its activation, and then down-regulation of S1PR1, preventing lymphocytes from infiltrating into the blood from lymphoid tissues, leading to a decrease in peripheral lymphocytes and limiting inflammation. 136 (Figure 4 ) FTY720 can also be used as a functional antagonist to desensitize the intracellular S1PRs pathway and inactivate the SIPR pathway in potential inflammatory cells. 138 Unlike most immunosuppressants, FTY720 prevents lymphocytes from penetrating into the blood from lymphoid tissues and does not cause cytotoxicity. 139, 140 As an FDA approved drug, FTY720 has the potential to help intervene and treat the more serious neurological side effects of SARS-Cov-2 infection. The FTY720 prodrug (FTY720-P) can cross the BBB and play a variety of direct roles in the CNS, from neuroprotection to reducing neuroinflammation. 67 FTY720-P inhibits the invasion of lymphocytes into the CNS by limiting the invasion of lymphocytes in the lymphatic tissue, thereby limiting neuroinflammation. 135 The maintenance of the S1P/S1PR signal can protect vascular endothelial function. 67 FTY720 blocks the inflammatory response mediated by S1P/S1PR1 and has a positive effect on against heart disease. 141 It has been observed to have a protective effect on acute and chronic myocardial damage in mice experiments with ischaemia and hypoxia. 142 Ozanimod is a S1PR agonist that targets S1PR1 and S1PR5, its function is similar to FTY720. When bound to S1PR1 and/or 5, it can lead to the internalization and degradation of S1PRs and the decrease of circulating lymphocytes. 143 As a selective S1PR1 agonist, AUY954 has been shown in animal experiments to reduce microvascular permeability and inflammation. 29 In contrast, the two S1PR1 antagonists W146 67

and NIBR-0213 145 showed a loss of capillary integrity in animal experiments.

As SARS-CoV-2 infection brings a cytokine storm, another serious complication, namely ARDS, is more likely to occur in elderly and severe cases of COVID-19 patients. 63, 146, 147 Recent studies have pointed out that compared with healthy controls, patients with ARDS have lower serum S1P levels, which is further related to non-pulmonary organ failure. 148 F I G U R E 4 A schematic diagram of the relationship between S1P and lymphocyte transport. Due to the high S1P concentration in circulation, S1PR1 of lymphocytes in circulation mostly internalized. After entering the secondary lymphoid organs with low S1P concentration, they gradually restore the surface expression of S1PR1 and regain the ability to egress from the lymphoid organs toward S1P in circulation. SphK 2 phosphorylates FTY720 and induces the internalization and subsequent degradation of S1PR1, thereby inhibiting the outflow of lymphocytes

As an immunomodulator, the effects of S1P analogues on host cells are diverse. We must clarify the potential risks of S1P analogues to the host. First of all, among the existing S1P analogues, only FTY720

is approved for the clinical treatment of multiple sclerosis. 154 FTY720 has broad specificity for S1PR1 and 3-5, and more precise S1P analogues, for instance, CYM5542 or RP-002, need to be studied to reduce off-target effects. Second, S1P analogues have shown good therapeutic potential in animal models of pulmonary infections, and their effects on humans have not been studied. Regarding the clinical treatment effect of FTY720 on COVID-19, clinical trials are currently underway. Third, the effect of S1P analogues on lymphocyte outflow does not involve agonism but is directed at the functional antagonistic activity of S1PR1. 155 It has been reported that both S1P and fingolimod phosphate induced lymphopaenia through agonistic activation of S1PR1 and subsequent internalization of S1P1 in lymphocytes. 154, 156, 157 Fourth, due to the lack of S1PR1 on the cell surface, the recirculation of lymphocytes from secondary lymphoid organs to the blood is blocked, 154 because lymphocytes flow out through S1PR1 by a chemotactic response to the S1P concentration gradient. 156, 158 For S1P, the internalized S1PR1 circulated back to the cell surface within a few hours. 139 But for S1PR1 modulators such as fingolimod phosphate, internalized S1PR1 underwent proteasomal degradation, resulting in a long-term lack of S1PR1 until it was synthesized de novo. 159 It has a long action time and sometimes may be detrimental to the body. 160 Considering the above factors, we must also consider all potential risks while exploring the huge therapeutic potential of S1P analogues.

Overall, S1P analogues may enhance the integrity of lung endothelial cells, and help to prevent and treat the nervous system damage caused by SARS-Cov-2 infection in the early stage. The cytokine storm induced by SARS-CoV-2 is a very serious immunopathology, which may cause the death of COVID-19 patients. S1P analogues protect against pulmonary infection earlier by suppressing cytokine storms. And the regulation of sphingolipid signalling has shown many beneficial effects, including selective vascular barrier protection, neuroprotection, limiting inflammation, regulation of coagulation, and cardioprotection. The regulation of S1P release or S1P content by S1P transporter, SphK or S1P lyase activity, and S1PRs-mediated signal transduction may prevent SARS-CoV-2 infection or virus transmission. Currently, three S1P-based drugs FTY720, Opaganib and Ozanimod, which have been approved by the FDA, have been considered for the treatment of COVID-19 patients, and clinical trials are currently underway, highlighting the potential of targeting SphK-S1P-S1PRs to alleviate symptoms in COVID-19 patients. S1P

analogues have great potential in the treatment of COVID-19, and further research is needed to explore the therapeutic effects and risks of S1P analogues in SARS-Cov-2 infected patients.

None.

The authors declare no conflicts of interest.

All authors contributed to the study conception and design.

Methodology, software, formal analysis: Yuehai Pan, Shuai Zhao, Jinming Han; writing-original draft preparation: Fan Chen, Fei Gao;

writing-review and editing: Fan Chen; all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

The data that support the findings of this study are openly available 

Letter to the editor: 'What are the long-term neurological and neuropsychiatric consequences of COVID-19?

SARS-CoV-2 infection: a role for S1P/S1P receptor signaling in the nervous system?

Clinical characteristics of 82 cases of death from COVID-19

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis

Coronavirus blood-clot mystery intensifies

Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology

Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China

Neurological manifestations of COVID-19: a systematic review and current update

SARS-CoV-2 can induce brain and spine demyelinating lesions

Nuclear lipids in the nervous system: what they do in health and disease

Sphingolipids and their metabolism in physiology and disease

Revisiting the sphingolipid rheostat: evolving concepts in cancer therapy

Sphingosine 1-phosphate: lipid signaling in pathology and therapy

Pro-survival lipid sphingosine-1-phosphate metabolically programs t cells to limit anti-tumor activity

The role of sphingosine-1-phosphate in inflammation and cancer progression

Regulation of immune cell migration by sphingosine-1-phosphate

Sphingosine-1-phosphate signaling in physiology and diseases

Sphingosine 1-phosphate signalling

Sphingosine 1-phosphate and cancer

Downregulation of sphingosine 1-phosphate receptor 1 promotes the switch from tangential to radial migration in the OB

Microarray-based discovery of highly expressed olfactory mucosal genes: potential roles in the various functions of the olfactory system

Sphingosine 1-phosphate promotes the proliferation of olfactory ensheathing cells through YAP signaling and participates in the formation of olfactory nerve layer

Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2

Sphingosine kinase mediates vascular endothelial growth factor-induced activation of ras and mitogen-activated protein kinases

Suppression of ceramidemediated programmed cell death by sphingosine-1-phosphate

Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling

Emerging connections of S1P-metabolizing enzymes with host defense and immunity during virus infections

Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice

Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate

Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2

Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration

A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity

Peripheral T cell depletion by FTY720 exacerbates hypoxic-ischemic brain injury in neonatal mice

Multiple sclerosis in the real world: a systematic review of fingolimod as a case study

Three phases of CD8 T cell response in the lung following H1N1 influenza infection and sphingosine 1 phosphate agonist therapy

Combination of sphingosine-1-phosphate receptor 1 (S1PR1) agonist and antiviral drug: a potential therapy against pathogenic influenza virus

Letter to the editor: "asymptomatic carrier transmission of coronavirus disease 2019 (COVID-19) and multipoint aerosol sampling to assess risks in the operating room during a pandemic

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in china

Reversing a model of Parkinson's disease with in situ converted nigral neurons

SARS-CoV-2 receptor and regulator of the reninangiotensin system: celebrating the 20th anniversary of the discovery of ACE2

A pneumonia outbreak associated with a new coronavirus of probable bat origin

The discovery of angiotensinconverting enzyme 2 and its role in acute lung injury in mice

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Structural basis of receptor recognition by SARS-CoV-2

Sphingosine prevents binding of SARS-CoV-2 spike to its cellular receptor ACE2

Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63

Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia

Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools

Angiotensin converting enzyme 2: a double-edged sword

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies

Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies

Vasculopathy and coagulopathy associated with SARS-CoV-2 infection

Clinical characteristics of coronavirus disease 2019 in China

Functional genomics highlights differential induction of antiviral pathways in the lungs of SARS-CoVinfected macaques

Battling COVID-19 pandemic: sphingosine-1-phosphate analogs as an adjunctive therapy? Front Immunol

Dysregulated type i interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

NLRP3 inflammasomes are involved in the progression of postoperative cognitive dysfunction: from mechanism to treatment

Reactive oxygen species interact with NLRP3 inflammasomes and are involved in the inflammation of sepsis: from mechanism to treatment of progression

Targeting the SphK-S1P-SIPR pathway as a potential therapeutic approach for COVID-19

Epigenetic regulation of pro-inflammatory cytokine secretion by sphingosine 1-phosphate (S1P) in acute lung injury: role of S1P lyase

Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget

Sphingosine kinase 2 in autoimmune/ inflammatory disease and the development of sphingosine kinase 2 inhibitors

Sphingosine kinase 2 is a negative regulator of inflammatory macrophage activation

Candidate drugs against SARS-CoV-2 and COVID-19

Host cell proteases: critical determinants of coronavirus tropism and pathogenesis

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus

Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection

Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human angiotensin-converting enzyme 2 virus receptor

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

SARS-CoV-2: olfaction, brain infection, and the urgent need for clinical samples allowing earlier virus detection

Central nervous system manifestations associated with COVID-19

Influenza and SARScoronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts

Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia

A transcriptomic atlas of mammalian olfactory mucosae reveals an evolutionary influence on food odor detection in humans

Olfactory epithelium: cells, clinical disorders, and insights from an adult stem cell niche

SARS-CoV-2 receptor and entry genes are expressed by sustentacular cells in the human olfactory neuroepithelium

Expression of the SARS-CoV-2 entry proteins, ACE2 and TMPRSS2, in cells of the olfactory epithelium: identification of cell types and trends with age

Proinflammatory cytokines in the olfactory mucosa result in COVID-19 induced anosmia

SARS-CoV-2 entry genes are most highly expressed in nasal goblet and ciliated cells within human airways

Neurological manifestations and complications of COVID-19: a literature review

Sphingosine-1-phosphate lyase expression in embryonic and adult murine tissues

Regulatory role of sphingosine kinase and sphingosine-1-phosphate receptor signaling in progenitor/stem cells

Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS

New insights into functions of the sphingosine-1-phosphate transporter SPNS2

MFSD2B is a sphingosine 1-phosphate transporter in erythroid cells

Neural sphingosine 1-phosphate accumulation activates microglia and links impaired autophagy and inflammation

Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions

Sphingosine 1-phosphate receptors regulate TLR4-induced CXCL5 release from astrocytes and microglia

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha

COVID-19 diagnosis and management: a comprehensive review

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Prevalence and severity of corona virus disease 2019 (COVID-19): a systematic review and meta-analysis

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options

The science underlying COVID-19: implications for the cardiovascular system

COVID-19, ACE2, and the cardiovascular consequences

A novel coronavirus from patients with pneumonia in China

Neurologic features in severe SARS-CoV-2 infection

COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features

Acute myelitis after SARS-CoV-2 infection: a case report

COVID-19 and intracerebral haemorrhage: causative or coincidental? New Microbes New Infect

Coronavirus disease 2019 and stroke: clinical manifestations and pathophysiological insights

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Remdesivir for the treatment of Covid-19 -final report

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Treatment of coronavirus disease 2019

Favipiravir, an anti-influenza drug against life-threatening RNA virus infections

Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing)

Ribavirin therapy for severe COVID-19: a retrospective cohort study

Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial

Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: a systematic review and meta-analysis

Teicoplanin: an alternative drug for the treatment of COVID-19?

Imbalanced host response to SARS-CoV-2 drives development of COVID-19

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Interferon β-1b in treatment of severe COVID-19: a randomized clinical trial

Interferon-a2b treatment for COVID-19

Dexamethasone in hospitalized patients with Covid-19 -preliminary report

Coronavirus pandemic-therapy and vaccines

Structure of the RNAdependent RNA polymerase from COVID-19 virus

Status of COVID-19 vaccine development

Open-label phase I clinical trial of Ad5-EBOV in Africans in China

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-inhuman trial

Sphingosine 1-phosphate receptors and metabolic enzymes as druggable targets for brain diseases

Sphingosine 1-phosphate and inflammation

Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases

Protection of ferrets from pulmonary injury due to H1N1 2009 influenza virus infection: immunopathology tractable by sphingosine-1-phosphate 1 receptor agonist therapy

Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases

The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: recent findings and new perspectives

Rethinking endothelial dysfunction as a crucial target in fighting heart failure

Sphingosine 1-phosphate signaling contributes to cardiac inflammation, dysfunction, and remodeling following myocardial infarction

Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity

Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2

Pathophysiological consequences of a break in S1P1-dependent homeostasis of vascular permeability revealed by S1P1 competitive antagonism

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Serum sphingosine-1-phosphate levels and Sphingosine-1-Phosphate gene polymorphisms in acute respiratory distress syndrome: a multicenter prospective study

Multifaceted roles for lipids in viral infection

Hiding in plain sight: an approach to treating patients with severe COVID-19 infection

Fingolimod induces neuronal-specific gene expression with potential neuroprotective outcomes in maturing neuronal progenitor cells exposed to HIV

Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod

Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal

Sphingosine 1-phosphate receptor modulators and drug discovery

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function

Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics

New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)

Immunosuppressive and antiangiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor

Sphingosine 1-phosphate receptor modulators in multiple sclerosis